Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA)

BACKGROUND: Pulmonary Arterial Hypertension (PAH) is a chronic rare disease that can lead to serious cardiovascular problems and death. Additional treatments that increase effectiveness, that are safe and with a convenient administration that improve outcomes and quality of life for patients are nee...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez, Alberto, Ais, Arantza, Beaudet, Amélie, Gil, Alicia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288887/
https://www.ncbi.nlm.nih.gov/pubmed/30526673
http://dx.doi.org/10.1186/s13023-018-0966-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288887/
https://www.ncbi.nlm.nih.gov/pubmed/30526673
http://dx.doi.org/10.1186/s13023-018-0966-4

Ejemplares similares